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        Rheumatoid arthritis (RA) is a chronic disease 
aff  ecting the peripheral joints in which abnor-
malities in the synovium precipitate a destruc-
tive process that often leads to cartilage and 
bone erosion. The autoimmune nature of this 
disease has been defi  ned, in part, through the 
presence of IgG autoantibodies such as rheu-
matoid factor and a tight genetic association 
with MHC class II molecules that contain a 
motif known as the shared epitope (SE) (  1, 2  ). 
This SE forms one of the major MHC class II 
anchoring pockets (known as P4) and imparts 
the ability to preferentially interact with certain 
amino acid side chains from antigenic peptides 
for subsequent presentation to CD4 T cells (  3  ). 
Because of these properties, the adaptive arm 
of the immune system has been implicated in 
driving disease pathogenesis through autoanti-
gen recognition. 
  Although many candidate autoantigens have 
been investigated in RA, a frequent target of 
the immune response found predominantly in 
this patient population has been lacking until 
recently. The discovery of serum IgG autoanti-
bodies from RA patients that bind posttransla-
tionally modifi  ed arginine (citrulline) within 
the context of certain proteins/peptides has 
provided an excellent diagnostic tool due in 
large part to their disease specifi  city (  4  –  7  ). The 
propensity to develop anti-citrulline antibodies 
is also associated with the expression of the 
SE, suggesting that an MHC class II  –  restricted 
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  Rheumatoid arthritis (RA) is a common autoimmune disease that affl  icts the synovium of 
diarthrodial joints. The pathogenic mechanisms inciting this disease are not fully character-
ized, but may involve the loss of tolerance to posttranslationally modifi  ed (citrullinated) 
antigens. We have demonstrated that this modifi  cation leads to a selective increase in 
antigenic peptide affi  nity for major histocompatibility complex (MHC) class II molecules 
that carry the RA-associated shared epitope, such as HLA-DRB1*0401 (DR4). We describe 
the induction of arthritis in DR4-IE transgenic (tg) mice with citrullinated fi  brinogen, a 
protein commonly found in infl  amed synovial tissue and a frequent target of autoanti-
bodies in RA patients. The disease induced in these mice was characterized by synovial hyper-
plasia followed by ankylosis, but lacked a conspicuous polymorphonuclear cell infi  ltrate. 
Immunological analysis of these mice through T cell epitope scanning and antibody micro-
array analysis identifi  ed a unique profi  le of citrulline-specifi  c reactivity that was not found 
in DR4-IE tg mice immunized with unmodifi  ed fi  brinogen or in wild-type C57BL/6 mice 
immunized with citrullinated fi  brinogen, two conditions where arthritis was not observed. 
These observations directly implicate citrullinated fi  brinogen as arthritogenic in the context 
of RA-associated MHC class II molecules. 968 HLA AND CITRULLINATED FIBRINOGEN | Hill et al.
modifi  ed hFib and assessed for clinical signs of arthritis. 
Although DR4-IE tg mice immunized with hFib did not 
develop arthritis during an extended observation period 
(200 d), immunization with CithFib induced arthritis in     35% 
of tg mice. Joint swelling typically ensued 10 wk after pri-
mary immunization (  Fig. 1 and Fig. 2 A  ) and was almost 
completely restricted to the ankles (one arthritic mouse also 
developed dactylitis in one forepaw).      The disease had a pro-
gressive and persistent course, beginning with mild swelling 
followed by severe erythema, eventually leading to ankylosis. 
Clinically evident swelling lasted for up to 6 wk, and restricted 
plantarfl  exion persisted in arthritic mice that were observed 
for an extended period (200 d). 
  To determine whether this arthritis was restricted by ex-
pression of the human DR4 transgene, wild-type C57BL/6 
(B6) mice were also immunized with these antigens and 
observed for arthritis. Clinical signs of disease did not develop 
in B6 mice after immunization with these proteins. Arthritis 
did not develop in either strain after immunization with 
mechanism may initiate this immune response (  8  –  10  ). We have 
shown that the conversion of arginine to citrulline at the 
peptide side chain position that interacts with the P4 pocket 
formed by the SE leads to a profound increase in MHC  –
  peptide affi   nity and to the subsequent activation of CD4 T 
cells (  11  ). This phenomenon is caused by the diff  erent charge 
interactions made between the MHC class II P4 pocket (pos-
itively charged because of arginine or lysine at position 71 of 
the      chain) and either peptide-bound arginine (positively 
charged because of the terminal amino group) or citrulline 
(polar and uncharged because of the terminal carbonyl group), 
where the latter interaction is preferred. These observations 
suggest that MHC class II  –  restricted CD4 T cells may propa-
gate the autoimmune response to citrullinated self-antigens 
found in RA patients. 
  Although the substrate of anti-citrulline antibodies was 
initially identifi  ed as citrullinated fi  laggrin (a protein that is 
found in the cornifi  ed layer of the skin, but not the joint), 
further investigation determined that citrullinated fi  brinogen 
is a synovial-derived target (  12  ). Because the expression of 
peptidylarginine deiminase, the enzyme responsible for con-
verting protein-bound arginine to citrulline, has been found to 
colocalize with fi  brin deposits and other intracellular citrullinated 
proteins (possibly vimentin) within RA synovial tissue (  13  –  15  ), 
it is likely that these autoantigens can be generated in the 
rheumatoid lesion. This, in addition to fact that autoantibodies 
that bind citrullinated fi  brinogen are frequently and specifi  -
cally found in RA patients, implicate this autoantigen in dis-
ease etiology (  16  –  18  ). 
  We provide evidence that citrullinated fi  brinogen is arth-
ritogenic in mice made tg for the RA-associated MHC class II 
molecule DRB1*0401 (DR4-IE tg mice). Immunization 
of DR4-IE tg mice with citrullinated, but not unmodifi  ed, 
human fi  brinogen (hFib) induced a progressive arthritic con-
dition characterized by synovial fi  broblast-like cell hyper-
plasia and the transient appearance of citrullinated proteins in 
the joints, but lacked signifi  cant infl  ammatory cell infi  ltra-
tion. Notably, wild-type C57BL/6 (B6) mice expressing mu-
rine H-2  b   were not susceptible to this disease, potentially 
owing to the fact that distinct diff  erences in the immune re-
sponse were found to be mediated by the HLA transgene. 
Although these results implicate citrullinated fi  brinogen as an 
arthritogenic antigen in the context of the RA-associated 
MHC class II molecule DRB1*0401, they also suggest that 
this HLA-restricted immune response may provoke arthritis 
in the absence of a robust and persistent polymorphonuclear 
cell infi  ltrate. 
    RESULTS   
  Induction of arthritis in DR4-IE tg mice 
  To determine the MHC class II  –  restricted arthritogenicity of 
citrullinated antigens, we chose to explore the immune re-
sponse to citrullinated fi  brinogen, a protein that is found in 
the diseased synovium of RA patients and is a target of auto-
antibodies in this disease (  12, 14  –  18  ). DR4-IE tg mice were 
immunized with either citrullinated hFib (CithFib) or un-
    Figure 1.         Clinical and histological evaluation of arthritis induced 
by CithFib in DR4-IE tg mice.   (A) Normal ankle joint of a DR4-IE tg 
mouse immunized with hFib (day 70). (B) Maximal swelling in an arthritic 
DR4-IE tg mouse immunized with CithFib (day 70). (C) Progression of 
arthritis showing reduced erythema in an arthritic DR4-IE tg mouse im-
munized with CithFib (day 150). Corresponding HE-stained histological 
sections of tibiotalar joints from nonarthritic and arthritic DR4-IE tg mice 
(D  –  F from mice shown in A  –  C, respectively). (D) Normal histological ap-
pearance of synovial membrane and cartilage surfaces. (E) Hyperplastic 
synovium showing some areas of cartilage damage, but lacking conspicu-
ous infl  ammatory cell infi  ltration. (F) Ankylosed joint showing fi  brotic 
changes in the tissues spanning the talus and navicular bones. (G) High-
powered magnifi  cation of normal synovial lining from a nonarthritic 
DR4-IE tg mouse immunized with hFib (day 70). (H) Synovial hyperplasia 
of the lining layer with subtle lymphocyte infi  ltration (arrows). This is 
representative of the earliest histological abnormality seen in arthritic 
DR4-IE tg mice immunized with CithFib. (I) Pannus tissue in an arthritic 
DR4-IE tg mouse highlighting areas of cartilage degradation. Bar, 100   μ  m.     JEM VOL. 205, April 14, 2008 
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at bone and cartilage interfaces (  Fig. 1   and Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20072051/DC1). 
Surprisingly, although synovial sublining infl  ammatory  cells 
were evident in arthritic DR4-IE tg mice, their presence was 
less conspicuous compared with other disease models, such 
as streptococcal cell wall  –  induced arthritis (unpublished data) 
(  19  ) or the arthritis seen in K/BxN tg mice (  20  ). To accurately 
quantitate the degree and type of infi  ltrate in the synovial 
tissue, we compared arthritic DR4-IE tg mice with the well-
characterized K/BxN model. Contrasting cellular content by 
high-power view quantifi  cation revealed a stark diff  erence in 
the degree of polymorphonuclear cell infi  ltration that domi-
nated the infi  ltrate in K/BxN mice, whereas arthritic DR4-IE 
tg mice showed a small but signifi  cant increase in lympho-
cytes (  Fig. 2 B  ). 
  Histological abnormalities persisted in the ankle joints of 
arthritic DR4-IE tg mice assessed at later stages of disease 
(  >  150 d after primary immunization;   Fig. 1 F  ) and showed 
fi  brotic synovial tissue in joint spaces, which is consistent 
with the clinical appearance of ankylosis. Other histological 
abnormalities were rarely seen outside of the ankle joint of 
arthritic mice, as the spine and major organs appeared normal 
(unpublished data). 
  We next addressed whether citrullinated protein was evi-
dent in the joints of arthritic mice by immunohistochemistry 
using an anti-modifi  ed citrulline (AMC) antibody (  Fig. 3, A  –  C  ).   
The most intense staining was found intracellularly in syno-
vial fi  broblast-like cells from hyperplastic tissue of mice with 
arthritis of recent onset. Some chondrocytes in the superfi  cial 
zone of articular surfaces were also found to stain with AMC; 
however, no citrullinated protein was identifi  ed at sites of 
cartilage or bone erosion or in ankylosed joints (unpublished 
data). Detection of fi  brin in serial sections ( Fig. 3, D –  F  ) showed 
mainly perivascular deposition in synovial tissues, but minimal 
colocalization with citrullinated protein, suggesting that other 
intracellular citrullinated proteins (possibly citrullinated vimen-
tin) could be present in the joints of these arthritic mice. 
citrullinated KLH, citrullinated mFib (CitmFib), or unmodifi  ed 
mFib (  Table I  ).   The development of arthritis was therefore 
dependent on the posttranslational modifi  cation (citrullination) 
of hFib and the expression of the RA-associated DRB1*0401 
MHC class II molecule. 
  Histological and immunohistochemical assessment 
of joint pathology 
  Histological analysis of tissues from arthritic mice revealed 
prominent synovial hyperplasia, with some pannus formation 
    Figure 2.         Joint swelling and histological analysis of infl  ammatory 
infi  ltrate in arthritic DR4-IE tg mice.   (A) Caliper measurements of 
DR4-IE tg mice immunized with CithFib were assessed every 7 d over 13 wk. 
Data are presented as mean      ankle width (  ±   the SEM), which was 
calculated by caliper measurements at the indicated time point, minus 
the preimmunization ankle width, from 12 individual arthritic mice (fi  lled 
circles) and 12 nonarthritic mice (open circles). P values were calculated 
by Student  ’  s   t   test. (B) High-powered view (hpv) histological analysis of 
infl  ammatory infi  ltrate in the joints of arthritic DR4-IE tg mice (day 70 
postimmunization) and K/BxN mice (8 wk old). Lymphocyte and polymor-
phonuclear cell content was determined by nuclear morphology in HE-
stained sections from hyperplastic synovial tissue. Points represent the 
number of cells identifi  ed in each high power view (63x objective), with 
54 individual views from 5 arthritic DR4-IE tg mice and 15 views from 2 
arthritic K/BxN mice. P values were obtained by Mann-Whitney test.     
    Table I.        Summary of immunizations and incidence of 
arthritis in DR4-IE tg and B6 mice 
Mouse strain Immunizing 
antigen
Mice immunized Arthritic mice
  % 
DR4-IE tg CithFib 135 48 (35.5) 
DR4-IE tg hFib 24 0
DR4-IE tg CitmFib 14 0
DR4-IE tg mFib 14 0
DR4-IE tg CitKLH 8 0
B6 CithFib 14 0
B6 hFib 14 0
B6 CitmFib 8 0
B6 mFib 8 0
Immunizations were conducted as outlined in Materials and methods. All mice were 
observed for at least 70 d after primary immunization, with the maximum 
observation period for some groups being 200 d.970 HLA AND CITRULLINATED FIBRINOGEN | Hill et al.
to murine H-2  b  , the HLA-DRB1 transgene can generate a 
strong citrulline-specifi  c T cell response characterized by the 
production of high levels of IFN-     and IL-10 and mediates 
cross-reactivity to CitmFib. 
  To understand the pathogenic potential of this citrulline-
specifi  c T cell response in DR4-IE tg mice, we established a 
cell transfer system. Here, we immunized and boosted DR4-
IE tg mice with CithFib, harvested splenocytes at day 31, 
and activated them in vitro with CithFib for an additional 
4 d. At the end of this culture, viable cells were isolated (of 
which   >  85% were CD4  +   by FACS) and transferred IP to 
DR4-IE tg recipients that received an intraarticular injection 
of CithFib, hFib, CitmFib, mFib, or BSA (Fig. S3, available at 
http://www.jem.org/cgi/content/full/jem.20072051/DC1). 
In this transfer system, only recipients that received an intra-
articular injection of CithFib developed arthritis, suggesting 
that CithFib-specifi  c T cells can drive disease, but only when 
the cognate antigen is found within the joint. 
  Identifi  cation of DR4-restricted T cell epitopes 
  Using a predictive model for identifying DR4-binding epi-
topes (  23  ), we selected all peptides within the     ,     , and      
chain of hFib that would contain the required P1 anchor (ali-
phatic or aromatic amino acid), an arginine or citrulline at the 
P4 SE position, and a noninhibitory amino acid at the P6 
  anchor. This resulted in the identifi  cation of 10 peptides, 7 
originating from the      chain, 2 from the      chain, and 1 from 
the      chain of fi  brinogen. To monitor the immune response 
to heterologous regions of hFib, we also synthesized a DR4-
binding peptide (Fib      371-383  ) that is found exclusively in the 
     chain of hFib and lacks arginine (  Fig. 5 C  ).   These peptides 
were used to monitor T cell recall responses in the two strains 
of mice at day 70 after immunization with CithFib or hFib. 
  Assessment of T cell responses 
  Splenic T cell responses to various forms of fi  brinogen were 
assessed by proliferation and cytokine production in both 
DR4-IE tg and B6 mice 70 d after primary immunization. 
Antigen-specifi  c proliferation in response to CithFib in DR4-IE 
tg mice immunized with this antigen was prominent and 
consistently higher than the response to hFib in individual 
mice (  Fig. 4 A  ).   B6 mice also showed citrulline-specifi  c re-
activity in this context; however, proliferation was approxi-
mately twofold lower than that seen in DR4-IE tg mice. 
Recall proliferative responses were detected in both strains 
after immunization with hFib, but in this circumstance, aug-
mented reactivity to CithFib was not detected. 
  Clear diff  erences in cytokine production were also evident, 
and paralleled responses identifi  ed by proliferation. After im-
munization with CithFib, DR4-IE tg mice produced high lev-
els of IFN-     after in vitro challenge with CithFib; again, much 
of this response appeared to be citrulline specifi  c (  Fig. 4 B  ). 
These levels of IFN-     production were also increased     10-
fold compared with B6 mice immunized with the same antigen 
or with either strain after immunization with hFib (  Fig. 4 C  ). 
A similar trend in cytokine production was also observed for 
IL-10 (Fig. S2, available at http://www.jem.org/cgi/content/
full/jem.20072051/DC1), suggesting that a highly polarized 
Th1 response occurred (  21, 22  ). IL-4 production was not 
detectable in these cultures (unpublished data). 
  We also tested for T cell reactivity to the endogenous an-
tigens CitmFib and mFib and found that only DR4-IE tg 
mice that were immunized with CithFib produced an im-
mune response to CitmFib (  Fig. 4, A, D, and E  ). Of particu-
lar note, although T cell reactivity to unmodifi  ed hFib was 
frequently detected in DR4-IE tg mice, no responses to un-
modifi  ed mFib occurred. These results show that in contrast 
    Figure 3.         Immunohistochemical localization of citrullinated proteins and fi  brinogen deposition in arthritic DR4-IE tg mice.  Citrullinated  pro-
tein was identifi  ed in arthritic mice 70 d after immunization with CithFib by staining with AMC antibodies in areas of synovial hyperplasia (A), with the 
most intense staining identifying intracellular proteins in synovial fi  broblast cells (B). (C) Nonarthritic mice immunized with hFib did not stain positive for 
AMC in these regions. Although fi  brin deposition was evident in perivascular regions of synovial tissue in arthritic mice (D), colocalization with citrul-
linated protein was minimal and virtually absent in areas of intense AMC staining (E). (F) No fi  brin deposition was detected in joints of nonarthritic mice 
immunized with hFib. Control staining without the primary antibody for each section is shown in the insets. Bar, 100   μ  m.     JEM VOL. 205, April 14, 2008 
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immunized with hFib and in B6 mice immunized with either 
antigen. The HLA-restricted response to the      chain peptide 
in CithFib immunized DR4-IE tg mice was further con-
fi  rmed by incubating splenocytes in the presence of anti-DR 
antibody and Fib      R84Cit  , which completely inhibited prolif-
eration (Fig. S4). 
  The immunogenicity of the peptides Fib     371-383  , Fib     R84Cit  , 
and Fib      79-91   was also assessed by immunizing DR4-IE tg 
mice with each peptide and characterizing the recall prolifera-
tive response to these antigens. Both Fib      371-383   and Fib      R84Cit   
induced T cell proliferation after in vitro challenge with the 
cognate peptide, whereas Fib     79-91   did not ( Fig. 5 B ). Although 
T cell reactivity to Fib      371-383   and Fib      R84Cit   was evident in 
DR4-IE tg mice after peptide immunization, neither peptide 
induced arthritis (observed until day 70). No response was seen 
in B6 mice. These data clearly confi  rm the DR4-restricted 
T cell response to heterologous regions of hFib and identify 
a citrulline-specifi  c epitope restricted by this human MHC 
class II molecule. 
  Assessment of antibody responses 
  To determine if anti-citrulline antibodies were produced in 
the two strains of mice, we tested for serum IgG reactivity 
to citrullinated and unmodifi  ed forms of mFib by ELISA. 
These antigens were chosen because initial studies using hFib 
and CithFib showed extremely high titers (  >  1:64,000) with 
no discernable diff  erence in antibody reactivity between 
either antigen. 
  In DR4-IE tg mice immunized with CithFib, a signifi  -
cant increase in IgG antibody reactivity to CitmFib was seen 
(  Fig. 6 A  ).   Weaker IgG reactivity to mFib was also evident, 
but was not signifi  cantly diff  erent from that seen in DR4-IE 
tg or B6 mice immunized with hFib. Although antibody 
reactivity to CitmFib was signifi  cantly higher in DR4-IE tg vs. 
B6 mice after immunization with CithFib, a weak but clearly 
evident citrulline-specifi  c response could be detected in mice 
that lacked the SE sequence (confirmed by inhibition; 
Fig. S5, available at http://www.jem.org/cgi/content/
full/jem.20072051/DC1). 
  Because T cells reactive with epitopes unique to hFib 
(and thus foreign) could provide help to citrulline-specifi  c B 
cells in B6 mice, we also tested IgG antibody reactivity in 
both strains after immunization (day 100) with citrullinated 
or unmodifi  ed autologous mFib. Under these conditions, the 
production of citrulline-specifi  c IgG was clearly confi  ned to 
mice that carried the SE (  Fig. 6 B  ). In fact, the antibody reac-
tivity was similar to that seen in human RA patients, as sig-
nifi  cant reactivity to self- (autologous) unmodifi  ed fi  brinogen 
was not observed (  18  ). 
  IgG profi  ling using synovial proteome microarray 
  To gain further insight into IgG specifi  city, we assessed serum 
reactivity to hundreds of unique protein and peptide antigens 
implicated in RA pathogenesis using antibody microarray. 
These arrays contained overlapping peptides spanning the full 
length of the      and      chains of fi  brinogen in both citrullinated 
  As expected, HLA-DRB1*0401  –  restricted T cell reac-
tivity to Fib      371-383   (measured by proliferation and IFN-     
production) was evident in DR4-IE tg mice after immuniza-
tion with either CithFib or hFib, whereas no recall response 
to this peptide was seen in B6 mice (  Fig. 5 A  ). Of the 10 fi  -
brinogen peptides containing citrulline at the P4 position, 
only one peptide from the      chain (Fib      R84Cit  ) consistently 
induced strong IFN-     production in DR4-IE tg mice im-
munized with CithFib, whereas no response was seen against the 
corresponding arginine-containing peptide Fib      79-91   (  Fig. 5 A   
and Fig. S4, available at http://www.jem.org/cgi/content/
full/jem.20072051/DC1). Notably, this particular sequence 
is identical in both the human and mFib      chain (  Fig. 5 C  ). 
T cell reactivity to Fib      R84Cit   was absent in DR4-IE tg mice 
    Figure 4.         Antigen-specifi  c recall proliferation and cytokine pro-
duction in DR4-IE tg and B6 mice immunized with CithFib or hFib 
(day 70).   (A)    Splenocytes were cultured in the presence of 50   μ  g/ml of 
the indicated in vitro antigens and proliferation (shown as stimulation 
index) was determined by [  3  H]thymidine incorporation. (B  –  E) Supernatant 
from these cultures were removed at 72 h and tested for the presence of 
IFN-     by ELISA. Individual (fi  lled circles) and mean (open boxes) responses   ±   
the SEM (proliferation) or the SD (IFN-    ) are shown (  n   = 6 mice/strain/
immunizing antigen). * indicates signifi  cant difference in cytokine produc-
tion between DR4-IE tg and B6 mice. P   <   0.05, paired Student  ’  s   t   test.   972 HLA AND CITRULLINATED FIBRINOGEN | Hill et al.
patients (  8, 15, 24  ). Diff  erential responses were noted for mul-
tiple citrullinated vimentin peptides, with increased antibody 
reactivity clearly biased in favor of DR4-IE tg mice after im-
munization with CithFib (  Fig. 6 D   and Table S3, available at 
http://www.jem.org/cgi/content/full/jem.20072051/DC1). 
Vimentin-derived targets that were signifi  cantly diff  erent be-
tween DR4-IE tg and B6 mice immunized with CithFib were 
vim286-305cit and vim256-275cit. Additional analysis through 
peptide-based ELISA assay with vim256-275cit confi  rmed the 
specifi  c HLA-restricted antibody reactivity seen by microarray 
(unpublished data). 
  Finally, pairwise comparison between DR4-IE tg and 
B6 mice immunized with CithFib was conducted to iden-
tify all signifi  cant diff  erences in antibody reactivity. Several 
epitopes outside of vimentin and fi  brinogen were high-
lighted (  Fig. 6 E  ). Of the epitopes specifi  cally targeted in 
DR4-IE tg mice,   >  50% were citrullinated, whereas the two 
targets of antibodies in B6 mice were derived from unmod-
ifi  ed fi  brinogen. 
  These results provide evidence that the HLA transgene 
mediates a distinct skewing in anti-citrulline antibody reac-
tivity, and suggests that immunization with CithFib can per-
petuate a wide range of IgG target recognition, which is 
indicative of broad cross-reactivity or epitope spreading. 
and unmodifi  ed forms, in addition to peptides from other 
candidate citrullinated autoantigens, notably vimentin. Serum 
samples from DR4-IE tg and B6 mice immunized with CithFib 
or hFib (day 70) were used to identify patterns of epitope 
recognition within and between strains. 
  We initially looked for diff  erential reactivity to fi  brino-
gen-derived antigens contained on the array and found that 
the HLA transgene, indeed, skewed the antibody response 
to multiple epitopes (  Fig. 6 C   and Table S1, available at 
http://www.jem.org/cgi/content/full/jem.20072051/DC1). 
This is highlighted by the fact that both strains responded 
to unique clusters of peptides after immunization with either 
form of antigen. The microarray platform also confi  rmed the 
increased reactivity to CitmFib that was seen in DR4-IE tg 
mice by ELISA. In general, a moderate degree of variability 
was seen in the IgG response to any particular fi  brinogen-
derived antigen from individual mice. As a result, the only 
signifi  cantly diff  erent IgG antibody response between B6 
and DR4-IE tg mice immunized with CithFib was the tar-
geting of the hFib      chain peptide 406  –  425 by B6 mice 
(  Fig. 6 E   and Table S2). 
  We next addressed IgG reactivity to vimentin in these sera 
because autoantibodies to this citrullinated antigen (also known 
as the Sa antigen) are a specifi  c marker of disease in RA 
    Figure 5.         T cell responses to fi  brinogen derived peptides in DR4-IE tg and B6 mice.   (A) Splenocytes from DR4-IE tg and B6 mice immunized with 
CithFib or hFib (day 70) were cultured in the presence of 50   μ  g/ml of either Fib     371  –  383 (left) or Fib     R84Cit (right). Supernatants from these cultures 
were removed at 72 h and tested for the production of IFN-     by ELISA. Individual (fi  lled circles) and mean (open boxes) responses   ±   the SD are shown (  n   =  6 
mice/strain/immunizing antigen). Labels above boxes indicate the antigen used for in vitro challenge, and labels within boxes indicate the immunizing 
antigen. * indicates signifi  cant difference in cytokine production between DR4-IE tg immunized with CithFib and hFib (P   <   0.05, paired Student’s   t   test). 
(B) Confi  rmation of peptide immunogenicity by antigen-specifi  c T cell proliferation. DR4-IE tg mice were immunized with either Fib     371 – 383  (left),  Fib   
R84Cit (middle), or Fib     79  –  91 (right); 10 d later, draining lymph node cells were cultured with various concentrations of peptide (Fib     R84Cit,  closed 
circle; Fib     79  –  91, open circle; Fib     371  –  383, inverted closed triangle). Data represent the mean response   ±   the SEM of six mice per immunizing antigen. 
(C) Peptides corresponding to human      chain sequences used in A and B for determining T cell recall responses. Amino acids differing between mouse 
Fib     371  –  383 are indicated in red. P4 amino acid from Fib     R84Cit and Fib     79  –  81 predicted to be positioned at the SE are indicated in green and red, 
respectively, with the corresponding sequence from the      chain  of  mFib.   JEM VOL. 205, April 14, 2008 
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In total, there were 16 arginine residues from the      chain and 
4 from the      chain of hFib that were not present in mouse. 
Many of these arginines were shown to be citrullinated in vitro 
by PAD2 or 4 (Table S4, available at http://www.jem.org/cgi/
content/full/jem.20072051/DC1, and unpublished data) (  25  ). 
We next searched for citrulline-specifi  c antibody reactivity 
to these regions (found in CithFib- but not hFib-immu-
nized DR4-IE tg mice), and then stratifi  ed for antibody reac-
tivity that was higher in DR4-IE tg versus B6 mice immunized 
  Xenoreactive antibody responses are evident to CithFib 
  Because arthritis was found after immunization with citrulli-
nated human, but not mouse, fi  brinogen in DR4-IE tg mice, 
we further characterized aspects of the xenoreactive immune 
response that may be important in this process by using anti-
body microarray data in combination with mass spectrometry 
sequencing of citrullinated fi  brinogen that was previously de-
scribed (  25  ). We fi  rst aligned the human and mFib sequences to 
identify heterologous regions where arginine substitutions occur. 
    Figure 6.         IgG antibody responses detected by ELISA and synovial proteome microarray.   (A) IgG reactivity to either CitmFib or mFib in DR4-IE tg 
or B6 mice 70 d after immunization with either CithFib or hFib. Mean OD of duplicates for individual serum are shown (  n   = 12 for DR4-IE tg mice immu-
nized with CithFib and   n   = 6 for all other groups). (B) Total IgG reactivity to either CitmFib or mFib in DR4-IE tg or B6 mice 100 d after immunization with 
either CitmFib or mFib (  n   = 7 for DR4-IE tg mice immunized with CitmFib and   n   = 5 for all other groups). * indicates signifi  cant difference in antibody 
reactivity (P   <   0.05, paired Student  ’  s   t   test) between all groups, whereas ** indicates signifi  cant difference in antibody reactivity to CitmFib in B6 mice 
immunized with CithFib versus reactivity to CitmFib in B6 or DR4-IE tg mice immunized with hFib (P   <   0.05, paired Student  ’  s   t   test). Analysis of serum IgG 
reactivity to fi  brinogen- (C) or vimentin-derived (D) peptides identifi  ed by SAM and grouped by Cluster based on relationships. (E) Pairwise analysis of 
signifi  cantly different IgG antibody reactivity between DR4-IE tg and B6 mice immunized with CithFib (P   <   0.05, Student  ’  s   t   test). Antigens shown were 
stratifi  ed based on having greater than fourfold increase in reactivity compared with immunization with hFib. Values shown are median subtracted and 
row normalized with relative expression shown in relation to scale bar. Raw data and peptide sequences can be found in Table S1 – S3,  available  at 
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with CithFib. From the antibody microarray data, and using 
the preceding selection criteria, we identifi  ed the      chain 
sequence 121-140cit (  Fig. 7 A  ) as a candidate target for a 
xenoreactive antibody response in DR4-IE tg mice (  Fig. 7, 
B and C  , and Table S4).   To confi  rm the species specifi  city in 
regard to the immunizing antigen, we synthesized a region of 
this peptide to test serum from DR4-IE tg mice immunized 
with CitmFib or mFib by ELISA. As predicted from the se-
quencing data, antibody reactivity to the Fib    123Cit pep-
tide was only found in DR4-IE tg mice immunized with 
CithFib, but not with CitmFib (  Fig. 7 D  ). These results iden-
tify a xenospecifi  c citrullinated B cell epitope that is targeted by 
the antibody response in HLA-DR4-IE tg mice immunized 
with CithFib. 
    DISCUSSION   
  In this study, we show that citrullinated fi  brinogen, an anti-
gen that is frequently targeted by autoantibodies in RA pa-
tients, can induce arthritis in mice that carry the RA-associated 
MHC class II SE allele   DRB1  *0401. This disease was re-
stricted by both the posttranslational modifi  cation of the 
antigen and the HLA transgene, as arthritis was not seen in 
mice administered unmodifi  ed fi  brinogen or in wild-type (B6) 
mice administered either form of fi  brinogen. Citrulline-spe-
cifi  c T and B cell responses were prominent in DR4-IE tg 
mice, but they were not absolutely restricted by the SE, as 
antibody reactivity to some citrullinated antigens could be 
detected by ELISA and antibody microarray profi  ling in B6 
mice. Further, although the arthritis in DR4-IE tg mice led 
to joint damage, and like RA, was accompanied by synovial 
cell hyperplasia, we did not fi  nd a robust and persistent poly-
morphonuclear cell infi  ltrate within joint tissues, suggesting 
that in this model, HLA-restricted responses to citrullinated 
fi  brinogen can recapitulate some, but not all, aspects of the 
rheumatoid pathology. 
  Evidence that, in large part, the SE regulates the produc-
tion of anti-citrulline antibodies in RA patients implies a 
causal relationship with disease pathogenesis mediated through 
CD4 T helper cell activation (  26, 27  ). We have shown pre-
viously that the increased affi   nity of peptide-bound citrulline 
versus arginine for RA-associated MHC class II molecules 
correlates with CD4 T cell activation, but whether these 
peptides can be processed from citrullinated fi  brinogen was 
not known. In this study, we addressed this question by as-
sessing T cell recall responses in DR4-IE tg and B6 mice af-
ter immunization with CithFib. The presence of the HLA 
SE transgene aff  orded citrulline-specifi  c T cell proliferation 
accompanied by IFN-     production after in vitro challenge 
with CithFib and CitmFib. We also assessed peptide-specifi  c 
recall responses to predicted DR4-binding epitopes and con-
fi  rmed that a strong HLA SE-restricted T cell response was 
    Figure 7.         IgG antibody responses to heterologous regions of 
CithFib and CitmFib.   (A) Amino acid substitutions between human 
and mFib are found in the      chain peptide 121  –  140 at arginine resi-
dues. Previous mass spectrometry analysis on in vitro CithFib identi-
fied     R123 and     R129 as sites of citrullination (  25  ). (B) Increased 
antibody reactivity is evident in DR4-IE tg mice immunized with CithFib 
compared with B6 mice or either strain after immunization with 
hFib. Values represent normalized arbitrary antibody units from micro-
array analysis with   n   = 5 mice/strain/immunization. (C) Antibody reac-
tivity to Fib    121-140Cit is citrulline specific because no reactivity is 
found to Fib    121-140. Values represent normalized arbitrary antibody 
units from microarray analysis with   n   = 5 mice/strain/immunization. 
(D) Antibody reactivity to Fib    123Cit in DR4-IE tg mice immunized 
with CithFib (  n   = 9), hFib (  n   = 5), CitmFib (  n   = 4), and mFib (  n   =  5) 
detected by ELISA. Mean OD of duplicates for individual serum 
are shown.     
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was noteworthy. Autoantibodies to citrullinated vimentin or 
Sa are strongly associated with disease severity and SE car-
riage in RA patients (  8  ), and a role in disease pathogenesis has 
been speculated for years. Vimentin  ’  s role as an intracellular 
intermediate fi  lament protein has been extensively studied; 
however, it is now evident that this protein is also present 
extracellularly, and could therefore interact directly with au-
toantibodies. Extracellular vimentin has been detected on 
platelets, macrophages, neutrophils, and T cells (  30, 32  –  35  ). 
It is not known if extracellular vimentin is citrullinated, but 
vimentin is seen in situations of cellular activation and apop-
tosis, two conditions where intracellular calcium fl  uxes oc-
cur, a process necessary to activate peptidylarginine deiminase. 
  A distinct feature of the arthritis seen in DR4-IE tg mice 
was pronounced synoviocyte dysregulation, but a relative 
paucity of polymorphonuclear cells within the joints com-
pared with other mouse models of arthritis. The reason for 
this is not known, but it is possible that a transient and self-
limiting infl  ammatory infi  ltrate (not captured at the time 
points of our histological examination) could have provided 
a stimulus for synovial hyperplasia. A discordant relationship 
between anti-citrulline immune responses and synovial in-
fl  ammatory cell infi  ltration has, however, been reported in 
RA patients. Baeten et al. have shown that anti-citrulline an-
tibody titers do not correlate with histological parameters of 
synovial infl  ammation, nor does local infl  ammation correlate 
with SE carriage (  14  ). Although not formally addressed in the 
current study, autoantibodies in this model could perpetuate 
disease by directly altering synovial fi  broblast or chondrocyte 
cellular homeostasis, as has been shown previously with IgG 
(  36, 37  ). Alternatively, a persistent and robust infl  ammatory 
cell infi  ltrate in the joint could be facilitated by additional ge-
netic insults (possibly in PTPN22 or Fc    RIII) that are inde-
pendent of the SE (  38  –  41  ). 
  This is the fi  rst description of citrulline-dependent arthri-
tis in mice. Previous studies in mice have shown that the state 
of citrullination can infl  uence disease severity in collagen-
induced arthritis and that citrullination can break tolerance, 
leading to the development of citrulline-specifi  c antibodies 
(  42  –  44  ). Recent work has also shown that murine mono-
clonal antibodies specifi  c for citrullinated fi  brinogen can aug-
ment arthritis through passive transfer with anti  –  collagen II 
antibodies (  45  ). Our studies show that the infl  uence of the 
HLA transgene in citrulline-specifi  c immune responses infl  u-
ences the magnitude and diversity of reactivity rather than 
the mere presence or absence of a response. These factors 
likely infl  uence disease expression, as thresholds for T cell re-
activity and antibody titers, as well as IgG epitope specifi  city, 
are limiting factors in other murine models of arthritis (  46  –  49  ). 
Threshold eff  ects may also be relevant to human disease, as 
prospective analysis of anti  –  cyclic citrullinated peptide anti-
bodies in healthy individuals who later go on to develop RA 
show a marked increase in titer before disease onset (  50, 51  ). 
  There are still unresolved issues pertaining to the model 
of arthritis presented in this study that require further explo-
ration. For instance, it is not known why   <  40% of the mice 
generated against both heterologous regions of hFib, and to 
a region of the      chain that was identical between species. 
The later peptide (Fib     R84Cit) contained citrulline at the 
critical P4 SE position and T cell responses in DR4-IE tg 
mice were restricted by this posttranslational modifi  cation. 
Notably, this was the only peptide within fi  brinogen that we 
identifi  ed with this stimulatory property after conversion 
from arginine to citrulline at P4. The signifi  cance of T cell 
reactivity to this epitope is not known, but sequencing data 
from in vitro citrullination shows that modifi  cation of argi-
nine at position 84 of the      chain is variable for hFib, whereas 
the same amino acid is consistently converted to citrulline 
after in vitro modifi  cation of mFib (unpublished data) (  25  ). 
Site-specifi  c citrullination within antigens highlights another 
level of variability that could impact the development of au-
toimmune responses. Moreover, whereas epitope specifi  city 
of the PAD enzymes have been assessed in vitro, naturally 
occurring citrullination sites within fi  brinogen (or other anti-
gens) have not been determined in vivo, or in other disease 
conditions besides RA. 
  In regard to HLA-restricted antibody responses, we found 
that characteristics of RA serum reactivity toward citrulli-
nated antigens were paralleled in these mice. First, as in 
human patients (  28  ), anti-citrulline antibodies were not 
completely restricted by the MHC class II SE, but instead 
levels were signifi  cantly higher in DR4-IE tg mice. This was 
evident by ELISA and antibody microarray profi  ling when 
assessing reactivity to CitmFib. Second, antibody reactivity 
to citrullinated antigens was broad, targeting sequences not 
only within fi  brinogen, but also antigens such as vimentin 
(the target of anti-Sa antibodies in RA patients), fi  bromodu-
lin, cartilage oligomeric protein (COMP), vitronectin, bigly-
can, and clusterin. Some of these proteins remain to be 
confi  rmed as targets of PAD in vivo, but all have been impli-
cated either in RA pathogenesis or synovial/cartilage ho-
meostasis. An unresolved issue with respect to anti-citrulline 
antibody specifi  city and evolution in RA patients is whether 
this broad response is the result of epitope spreading or merely 
cross-reactivity, which is a question that is not directly ad-
dressed in this study, but one that is currently being pursued. 
If epitope spreading is the cause, it would suggest that many 
of the proteins targeted by anti-citrulline antibodies are func-
tionally and/or physically associated. This may be true for 
some of the citrullinated aforementioned antigens, as fi  brino-
gen, vimentin, and vitronectin have been shown to associate 
during platelet activation, whereas fi  bromodulin, COMP, 
and biglycan are integral components of cartilage (  29  –  31  ). 
The polyreactive nature of this antibody response also con-
founds the interpretation of the potential arthritogenicity of 
autoantibodies solely directed against citrullinated fi  brinogen 
in this model and in RA. 
  It was interesting that several DR4-IE tg mice immu-
nized with CithFib responded uniquely to citrullinated pep-
tides from vimentin. The reactivity to Cit vimentin peptides 
derived from the C-terminal region of vimentin downstream of 
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when identifying a candidate T cell epitope (glutamine has the same terminal 
side chain group as citrulline). Fibrinogen-derived peptides spanning the se-
quences Fib      79  –  91, Fib      138  –  150, Fib      173  –  185, Fib      507  –  519, Fib      
673  –  685, Fib      715  –  727, Fib      738  –  750, Fib      69  –  81, Fib      280  –  292, and 
Fib      118  –  130 were synthesized in both arginine- and citrulline-containing 
forms, except for Fib      371  –  383, which does not contain arginine. 
  Assessment of arthritis.     Mice were monitored twice weekly for clinical 
signs of arthritis, and caliper measurements were taken once weekly. Three 
clinically apparent stages of disease were apparent, beginning with mild joint 
swelling, followed by severe erythema, and ending with reduced swelling 
accompanied by plantarfl  exion restriction upon physical examination. These 
clinical observations closely followed caliper measurements. Some arthritic 
mice killed at day 70 that showed mild clinical swelling were further con-
fi  rmed to have synovial abnormalities by histology. 
  Histological and immunohistological evaluation.     Mice were killed at 
the indicated time points, and the hind paws were dissected and fi  xed in 10% 
buff  ered formalin solution (VWR). Fixed tissues were decalcifi  ed for 5  –  7 d 
in 14% EDTA, followed by dehydration and paraffi   n embedding. Sagital 
sections (8   μ  m) were stained with hematoxylin and eosin (HE) or safranin O, 
or further processed for immunohistochemical staining. HE-stained sections 
were blindly assessed for joint abnormalities in DR4-IE tg mice immunized 
with CithFib or hFib at day 10, 31, and 70 after immunization (4 mice/im-
munizing antigen/time point). Additional arthritic mice were also assessed at 
day 70, 150, and 200. Sections from B6 mice immunized with CithFib or 
hFib (day 70) and DR4-IE tg mice immunized with CitmFib or mFib (day 
100) were blindly assessed (4 mice/immunizing antigen), but did not show 
abnormal pathology. Joints including knee, shoulder, elbow, wrist, and spine 
were assessed in representative arthritic and control mice by histology, but 
did not show abnormal pathology. Citrullinated proteins were detected as 
previously described (  54  ) using an AMC staining kit (Millipore) in combina-
tion with Vectastain ABC reagent (Vector Laboratories). Fibrinogen was 
detected using an anti-fi  brinogen antibody (DAKO) according to the manu-
facturer  ’  s instructions, in combination with Vectastain ABC reagent. 
  T cell cultures.     Cell suspensions were prepared from the spleen or draining 
lymph nodes of mice killed at the indicated time points and cultured in 
96-well plates at a concentration of 4   ×   10  5   cells/well in the presence or ab-
sence of protein or peptide antigen for 4 d. 18 h before culture termination, 
0.5   μ  Ci of [  3  H]thymidine (ICN Biomedicals) was added to each well to assess 
T cell proliferation. Proliferation experiments were conducted in triplicate, 
and results are presented as the mean stimulation index (cpm of experimental 
sample/cpm of control sample)   ±   the SEM. Supernatants were removed 
from cultures after 72 h for testing cytokine production by ELISA (BD Bio-
sciences), as previously described (  55  ). Cytokine production was measured 
in duplicate and represents the mean antigen-specifi  c cytokine production 
(cytokine production in control samples [no antigen in vitro] + 2 SD were 
subtracted from the protein- or peptide-specifi  c cytokine production)   ±   
the SD. 
  T cell transfers.     DR4-IE tg mice were immunized and boosted, as de-
scribed in Immunizations. Spleens were harvested at day 31, and processed 
for in vitro stimulation with CithFib, as described in T cell cultures. 4 d after   
in vitro stimulation,viable cells were harvested by Ficoll gradient centrifuga-
tion and assessed for CD4 content by FACS (  >  85% positive). Cells then 
were transferred i.p. (10   ×   10  6  /mouse) and recipients received an intra-
articular injection of 5   μ  g of the indicated antigen in a total volume of 5   μ  l. 
Caliper measurements were taken on the ankles every day for 2 wk, and data 
are presented as mean      ankle width (mm;   ±   the SEM) for the indicated 
number of mice. 
  ELISA detection of antigen-specifi  c serum IgG.     Serum was collected 
from blood obtained by heart puncture from mice killed at the indicated time 
points. Antigen-specifi  c ELISA was performed as previously described (  18  ). 
develop disease, and we have not identifi  ed any 1 parameter 
of the immune response that signifi  cantly diff  erentiates ar-
thritic and nonarthritic DR4-IE tg mice immunized with 
CithFib (although arthritic mice did show a trend to higher 
cytokine responses and antibody production to certain antigens). 
In preliminary studies, we have induced a transient arthritis 
in DR4-IE tg mice after the transfer of citrulline-specifi  c 
CD4  +   T cells or anti-citrulline antibodies, directly implicat-
ing these mediators in the disease process (Fig. S3 and unpub-
lished data) (  52  ). 
  We have also found that CitmFib, an antigen that can 
evoke a citrulline-specifi  c immune responses in DR4-IE tg 
mice, is not arthritogenic. Our examination of heterologous 
regions of fi  brinogen that have been found to be citrullinated 
by mass spectrometry (  25  ), coupled with IgG antibody micro-
array and ELISA data, does suggest that reactivity to Fib    121-
140Cit may be important to this species-specifi  c response. It 
is possible that reactivity to this sequence provides a platform 
for cross-reactivity to other proteins (such as vimentin), but a 
role in pathogenesis requires further examination. 
  In conclusion, these results indicate that in genetically 
susceptible DR4-IE tg mice, citrullinated fi  brinogen can 
drive an autoimmune response that is associated with the 
development of arthritis. Further exploration of this model 
will help elucidate the role and contribution of SE-restricted 
T and B cell responses to citrullinated antigens in the patho-
genesis of RA. 
    MATERIALS AND METHODS   
  Mice.     DR4-IE tg murine MHC class II  –  defi  cient mice (  53  ) were bred at 
the John P. Robarts Barrier Facility and C57BL/6 (B6) mice were purchased 
from The Jackson Laboratory. Both strains were housed in the Animal Care 
and Veterinary Services Barrier Facility at the University of Western Ontario 
under specifi  c pathogen  –  free conditions. The work with these mice was 
performed according to the guidelines established by the Canadian Council 
on Animal Care. 12  –  14-wk-old male mice were used in these experiments, 
as initial studies showed the incidence of arthritis to be higher than in fe-
males. 8-wk-old K/BxN mice used for histological analysis were maintained 
as previously described, and all procedures were approved by the Dana-Far-
ber Cancer Institute Animal Care and Use Committee (  20  ). 
  Immunizations.     Mice were immunized subcutaneously on the inner 
thigh/fl  ank with 100   μ  g protein or peptide antigen in CFA (1:1 volume of 
antigen and IFA supplemented with 4 mg/ml   Mycobacterium tuberculosis   
HA37) in a total volume of 100   μ  l. Boosting immunizations with protein 
antigens were conducted with the same concentration and volume of anti-
gen in IFA 21 d later. 
  Protein antigens.     Purifi  ed human (Calbiochem) and mFib (Innovative 
Research, Inc.) were used in both citrullinated and unmodifi  ed  form, 
whereas KLH (Sigma-Aldrich) was used in the citrullinated form. Citrullina-
tion of fi  brinogen was performed as previously described (  18  ) and confi  rmed 
by mobility shift in SDS-PAGE (Fig. S6, available at http://www.jem.org/
cgi/content/full/jem.20072051/DC1), Western blotting with human RA 
sera, and antigen-specifi  c ELISA. 
  Peptide antigens.     Peptides used in these studies were synthesized and puri-
fi  ed by the manufacturer (Genemed Synthesis). Peptides were selected based 
on their predicted affi   nity for DRB1*0401 according to the method of 
Hammer et al. (  23  ). Because citrulline is not accounted for in the predictive 
algorithm of Hammer et al., the value of glutamine was substituted for arginine JEM VOL. 205, April 14, 2008 
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In brief, MaxiSorp (Nunc) plates were coated with citrullinated and unmod-
ifi   ed forms of fi   brinogen, or the Fib    123Cit peptide (FSSANNCitDN-
TYNR), at a concentration of 10   μ  g/ml (100   μ  l/well) in carbonate coating 
buff  er overnight at 4  °  C. After washing with PBS and 0.05% Tween (PBST) 
and blocking with PBS 0.1% BSA, serum samples were diluted 1:100 in 
PBST 0.1%BSA and were incubated in duplicate for 2 h at room tempera-
ture. After washing again with PBST, biotin-conjugated anti  –  mouse IgG 
secondary antibodies (Sigma-Aldrich) were diluted 1:2,000 in PBST 0.1% 
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cantly diff  erent antibody reactivity between DR4-IE tg and B6 mice immu-
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peptide sequences can be found in Table S1  –  S3. 
  Online supplemental material.     Fig. S1 shows histological evaluation of 
arthritis in DR4-IE tg mice highlighting proteoglycan changes by safranin O 
staining. Fig. S2 shows that splenocytes from DR4-IE tg mice immunized 
with CithFib (day 70) produce IL-10 after in vitro challenge with CithFib or 
hFib. Fig. S3 shows that T cells from CithFib-immunized DR4-IE tg mice 
can induce arthritis after transfer to naive DR4-IE tg hosts that received 
intraarticular injection of CithFib. Fig. S4 shows the HLA-DR  –  restricted 
immune response to Fib     R84Cit in DR4-IE tg mice immunized with 
CithFib. Fig. S5 shows the citrulline-specifi  c antibody reactivity determined 
by inhibition. Fig. S6 shows the typical mobility shift of CithFib seen by 
SDS-PAGE. Table S1  –  S3 show the raw data and peptide sequences for the 
synovial proteome microarray analysis presented in   Fig. 6 (C  –  E)  , respec-
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activity by synovial microarray analysis. The online version of this article is 
available at http://www.jem.org/cgi/content/full/jem.20072051/DC1. 
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